What is the latest evidence on the use of romosozumab and how has the cardiovascular risk evolved?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18869784
Cited by: 0

Abstract

Romosozumab increases bone mineral density and reduces fracture risk but carries potential cardiovascular risks. Careful assessment is advised, particularly for patients with pre-existing cardiovascular conditions.

Fields of Study & Subjects

Bone health and osteoporosis research Bone health and treatments Menopause: Health Impacts and Treatments

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
5 March 2026
Language
EN